Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus gemcitabine in pancreatic adenocarcinoma
NCT03807999Phase 2Completed
- Sponsor
- Hacettepe University
- Start
- Feb 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Hacettepe University. Started Feb 2015; status: completed.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03807999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807999.